[1] 康阳阳,刘章锁,刘东伟. 中国成人慢性肾脏病患病率荟萃分析[J]. 中国实用内科杂志,2016,36(9):785-789.
[2] Wynn TA.Cellular and molecular mechanisms of fibrosis[J]. J Pathol, 2008, 214(2):199-210.
[3] Hoerger TJ, Simpson SA, Yarnoff BO, et al.The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative[J]. Am J Kidney Dis, 2015, 65(3):403-411.
[4] 赵胜,周向军,程帆. 外泌体在肾纤维化中的研究进展[J]. 医学综述,2020,26(5):839-844.
[5] Sun YB, Qu X, Caruana G, et al.The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis[J]. Differentiation, 2016, 92(3):102-107.
[6] 袁倩,刘友华. RF的细胞和分子机制研究进展[J]. 安徽大学学报(自然科学版),2018,42(5):115-124.
[7] Yang Z, He LJ, Sun SR.Role of Endothelial Cells in Renal Fibrosis[J]. Adv Exp Med Biol, 2019, 1165:145-163.
[8] Fogo AB, Kon V.The glomerulus--a view from the inside--the endothelial cell[J]. Int J Biochem Cell Biol, 2010, 42(9):1388-97.
[9] Markwald RR, Fitzharris TP, Smith WN.Sturctural analysis of endocardial cytodifferentiation[J]. Dev Biol, 1975, 42(1):160-180.
[10] Eisenberg LM, Markwald RR.Molecular regulation of atrioventricular valvuloseptal morphogenesis[J]. Circ Res, 1995, 77(1):1-6.
[11] Hong L, Du X, Li W, et al.EndMT: A promising and controversial field[J]. Eur J Cell Biol, 2018, 97(7):493-500.
[12] Piera-Velazquez S, Li Z, Jimenez SA.Role of endothelial-mesenchymal transition (EndMT) in the pathogenesis of fibrotic disorders[J]. Am J Pathol, 2011, 179(3):1074-1080.
[13] Rieder F, Kessler SP, West GA, et al.Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis[J]. Am J Pathol, 2011, 179(5):2660-2673.
[14] Wesseling M, Sakkers TR, de Jager SCA, et al. The morphological and molecular mechanisms of epithelial/endothelial-to-mesenchymal transition and its involvement in atherosclerosis[J]. Vascul Pharmacol, 2018, 106:1-8.
[15] Li L, Chen L, Zang J, et al.C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease[J]. Metabolism, 2015, 64(5):597-610.
[16] Sun X, Nkennor B, Mastikhina O, et al.Endothelium-mediated contributions to fibrosis[J]. Semin Cell Dev Biol, 2020, 101:78-86.
[17] Liu Y.Cellular and molecular mechanisms of renal fibrosis[J]. Nat Rev Nephrol, 2011, 7(12):684-696.
[18] Schmierer B, Hill CS.TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility[J]. Nat Rev Mol Cell Biol, 2007, 8(12):970-982.
[19] Medici D, Shore EM, Lounev VY, et al.Conversion of vascular endothelial cells into multipotent stem-like cells[J]. Nat Med, 2010, 16(12):1400-1406.
[20] Zeisberg EM, Potenta SE, Sugimoto H, et al.Fibroblasts in kidney fibrosis emerge via endothelial- to-mesenchymal transition[J]. J Am Soc Nephrol, 2008, 19(12):2282-2287.
[21] Li J, Qu X, Bertram JF.Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice[J]. Am J Pathol, 2009, 175(4):1380-1388.
[22] 张诗翊,胡晓茹,尚进,等. Chemerin/ChemR23与糖尿病肾病内皮-间质转分化的相关性研究[J]. 河南医学研究,2018,27(9):1537-1540.
[23] Liang X, Duan N, Wang Y, et al.Advanced oxidation protein products induce endothelial-to-mesenchymal transition in human renal glomerular endothelial cells through induction of endoplasmic reticulum stress[J]. J Diabetes Complications, 2016, 30(4):573-579.
[24] Lipphardt M, Dihazi H, Jeon NL, et al.Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition[J]. Nephrol Dial Transplant, 2019, 34(1):49-62.
[25] Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis[J]. Kidney Int(2010)78(Suppl 119): S22-S26.
[26] Weiskirchen R, Weiskirchen S, Tacke F.Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications[J]. Mol Aspects Med, 2019, 65:2-15.
[27] Pérez L, Muñoz-Durango N, Riedel CA, et al.Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions[J]. Cytokine Growth Factor Rev, 2017, 33:41-54.
[28] van Meeteren LA, ten Dijke P. Regulation of endothelial cell plasticity by TGF-β[J]. Cell Tissue Res, 2012, 347(1):177-186.
[29] Sureshbabu A, Muhsin SA, Choi ME.TGF-β signaling in the kidney: profibrotic and protective effects[J]. Am J Physiol Renal Physiol, 2016, 310(7):F596-F606.
[30] Yu L, Border WA, Huang Y, et al.TGF-beta isoforms in renal fibrogenesis[J]. Kidney Int, 2003, 64(3):844-856.
[31] Derada Troletti C, Fontijn RD, Gowing E, et al.Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology[J]. Cell Death Dis, 2019, 10(2):45.
[32] Chen HY, Huang XR, Wang W, et al.The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential[J]. Diabetes, 2011, 60(2):590-601.
[33] Maleszewska M, Moonen JR, Huijkman N, et al.IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner[J]. Immunobiology, 2013, 218(4):443-54.
[34] Chaudhuri V, Zhou L, Karasek M.Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts: a potential role in skin fibrogenesis[J]. J Cutan Pathol, 2007, 34(2):146-153.
[35] 张盟. CHOP基因敲除后抑制UUO诱导的小鼠肾脏纤维化的机制研究[D]. 华中科技大学,2016.
[36] Mack M.Inflammation and fibrosiss[J]. Matrix Biol, 2018,(68-69):106-121.
[37] Mahler GJ, Farrar EJ, Butcher JT.Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2013, 33(1):121-130.
[38] Lv W, Booz GW, Wang Y, et al.Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets[J]. Eur J Pharmacol, 2018, 820:65-76.
[39] 孟晓明,蓝辉耀. 转化生长因子-β与肾脏纤维化的研究进展[J]. 生理学报,2018,70(6):612-622.
[40] Liang XB, Ma LJ, Naito T, et al.Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth[J]. J Am Soc Nephrol, 2006, 17(7):1886-1895.
[41] Potenta S, Zeisberg E, Kalluri R.The role of endothelial-to-mesenchymal transition in cancer progression[J]. Br J Cancer, 2008, 99(9):1375-1379.
[42] LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis[J]. Nat Med, 2013, 19(8):1047-1053.
[43] 金芬,张忠寿,黄卫锋. 上皮间质转化和内皮间质转化在肾纤维化中的研究进展[J]. 海南医学,2014,25(18):2723-2725.
[44] Srivastava SP, Koya D, Kanasaki K.MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT[J]. Biomed Res Int, 2013, 2013:125469.
[45] Kumarswamy R, Volkmann I, Jazbutyte V, et al.Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21[J]. Arterioscler Thromb Vasc Biol, 2012, 32(2):361-369.
[46] Lyu H, Li X, Wu Q, et al.Overexpression of microRNA-21 mediates Ang II-induced renal fibrosis by activating the TGF-β1/Smad3 pathway via suppressing PPAR-α[J]. J Pharmacol Sci, 2019, 141(1):70-78.
[47] Meng XM, Tang PM, Li J, et al.TGF-β/Smad signaling in renal fibrosis[J]. Front Physiol, 2015, 6:82.
[48] 刘然. 高浓度胰岛素/高浓度葡萄糖干预下miR-21对肾小球内皮细胞功能的调节作用研究[D]. 天津医科大学,2019.
[49] Sun Q, Miao J, Luo J, et al.The feedback loop between miR-21, PDCD4 and AP-1 functions as a driving force for renal fibrogenesis[J]. J Cell Sci, 2018, 131(6):202-317.
[50] Kanasaki K, Shi S, Kanasaki M, et al.Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen[J]. Diabetes, 2014, 63(6):2120-31.
[51] Srivastava SP, Goodwin JE, Kanasaki K, et al.Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs[J]. Genes (Basel), 2020, 11(2):211.
[52] 张丹丹,梅峰. EndMT及其与纤维化疾病关系的研究进展[J]. 山东医药,2018,58(12):111-113.
[53] Ghosh AK, Nagpal V, Covington JW, et al.Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT[J]. Cell Signal, 2012, 24(5):1031-1036.
[54] Zhang H, Hu J, Liu L.MiR-200a modulates TGF-β1-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs[J]. Biomed Pharmacother, 2017, 95:215-222. |
